Explore the Agenda
8:30 am Check-In & Light Breakfast
8:50 am Chair’s Opening Remarks
Improving Antigen Selection, Translational Development & Manufacturing to Accelerate Personalized Cancer Vaccines Towards Approval
9:00 am From Promise to Practice: Enabling the Next Generation of Personalized Cancer Vaccines
- Exploring key learnings from clinical and translational development of individualized cancer vaccines
- Leveraging targeted antigen delivery to professional APCs to generate potent, broad, and long-lasting immune responses
- Addressing manufacturing complexity, scalability, and cost to make personalized immunotherapies a sustainable commercial reality
9:30 am Session Reserved for Almac
10:00 am From Neoantigen Prediction to Clinical Response: Following the Journey of a Personalized Cancer Vaccine
- Following the journey of a personalized cancer vaccine from neoantigen identification and AI-driven selection through vaccine design, manufacturing, and clinical administration
- Presenting translational insights from our clinical program by integrating immune monitoring, ctDNA dynamics, radiological assessment, and serial tumor biopsies to illustrate how different biomarkers capture vaccine activity
- Discussing how combining these complementary data provides a more comprehensive understanding of treatment response and clinical benefit, highlighting current challenges and future opportunities in personalized cancer vaccination
10:30 am Morning Networking Break
Improving Patient Outcomes by Selecting the Right Vaccine Approach to Achieve Potent & Efficacious Cancer Treatment
11:30 am Fireside Chat: Comparing Personalized vs. Off-the-Shelf Cancer Vaccines to Choose the Right Strategy for the Right Indication
- Which indications are best suited to personalized cancer vaccines and how can they provide clinical advantage?
- What are the key trade-offs between clinical outcomes, manufacturing scalability, speed to patients, and development costs?
- What will determine the long-term commercial success and patient accessibility of personalized versus off-the-shelf cancer vaccines?
12:00 pm Beyond Neoantigen Prediction: Using the Patient’s Own Tumour to Drive Personalised Cancer Vaccines
- Presenting CellVax’s Tumour Presenting Cell (TPC) platform, a personalised cancer vaccine approach that leverages the patient’s own tumour cells to present the full repertoire of tumour antigens without the need for neoantigen prediction algorithms
- Updating on the clinical and translational insights from the ongoing Phase 2 trial of FK-PC101 in high-risk prostate cancer patients following prostatectomy, including immune activation signals and long-term immunological responses
- Exploring how a tumour-derived antigen presentation may enable a simpler, faster, and potentially more scalable pathway for personalised cancer vaccines compared to sequencing-driven neoantigen approaches
12:30 pm Personalized Neoantigen Peptide Immunotherapy in Glioblastoma: From Pre-screening to Clinical Phase 1
- Pre-screening in glioblastoma – Identifying patients with sufficient tumor material and actionable neoantigen profiles for a personalized, targeted peptide-based immunotherapy
- Mechanistic basis and immune readouts – A targeted peptide-based approach designed to prime neoantigen-specific T-cell responses, with immune monitoring assays to capture activation, breadth, and durability
- Pathways to scalability – Identifying key drivers such as prediction accuracy, manufacturing performance, and workflow coordination that will enable future scaling of personalized peptide-based programs
1:00 pm Lunch & Networking Break
Unlocking the Potential of Personalized Cancer Vaccines with Robust Partnerships & Improved Patient Understanding
2:00 pm Accelerating the Future of Personalized Cancer Vaccines
- Introducing PICI’s unique model for accelerating cutting-edge cancer immunotherapies
- Exploring the evolving landscape and future potential of personalized cancer vaccines
- Discussing PICI’s role in advancing personalized cancer vaccine research and clinical development
2:30 pm Providing Clinical Perspectives on Personalized Cancer Vaccines
- Reviewing experience as a physician in enrolling patients on cancer vaccine trials
- Discussing clinical challenges during vaccine manufacturing timeline
- Sharing cases on PCV candidates and patient sentiment surrounding PCV
3:00 pm Afternoon Networking Break
Leveraging Novel Innovations in Delivery & Manufacturing to Reduce Timelines for Quicker Personalized Cancer Vaccine Production
4:00 pm Making Personalized Cancer Vaccines Accessible Alone & in Combination
- Preliminary data suggest that personalized cancer vaccines can be safe, effective at generating durable immunity, and possibly clinically effective in the adjuvant setting
- A major challenge, however, is cost and scalability
- Completely re-crafting the manufacturing process offers a way forward
4:30 pm Leveraging the LION Nanoformulation Technology to Unlock saRNA for the Development of Personalized Cancer Vaccines
- Showcasing the potential of LION for improved safety, stability and precise extrahepatic delivery of cancer immunotherapies
- Uncovering the superior T-cell response achieved from saRNA/LION vaccines
- Highlighting how LION delivery can transform manufacture, cost and logistics including quick, LNP-free, bedside preparation of personalized cancer vaccines for patients